$DVA
DAVITA INC.

2019 Q2 Form 10-Q Financial Statement

#000092706619000133 Filed on August 02, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2018 Q2
Revenue $2.843B $2.887B
YoY Change -1.53% 6.95%
Cost Of Revenue $1.958B $2.069B
YoY Change -5.38% 9.2%
Gross Profit $885.0M $817.9M
YoY Change 8.2% 1.64%
Gross Profit Margin 31.13% 28.33%
Selling, General & Admin $275.3M $262.0M
YoY Change 5.08% -0.08%
% of Gross Profit 31.11% 32.03%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $152.3M $147.1M
YoY Change 3.54% -26.45%
% of Gross Profit 17.21% 17.99%
Operating Expenses $427.5M $409.1M
YoY Change 4.5% 1.72%
Operating Profit $461.9M $438.2M
YoY Change 5.41% 12.01%
Interest Expense -$127.2M -$109.9M
YoY Change 15.74% 1.1%
% of Operating Profit -27.54% -25.08%
Other Income/Expense, Net $5.643M $1.994M
YoY Change 183.0% -58.44%
Pretax Income $323.7M $320.5M
YoY Change 1.0% 11.26%
Income Tax $75.94M $83.87M
% Of Pretax Income 23.46% 26.17%
Net Earnings $273.6M $267.3M
YoY Change 2.35% 110.45%
Net Earnings / Revenue 9.62% 9.26%
Basic Earnings Per Share $1.64 $1.56
Diluted Earnings Per Share $1.64 $1.53
COMMON SHARES
Basic Shares Outstanding 166.3M shares 171.6M shares
Diluted Shares Outstanding 166.8M shares 174.1M shares

Balance Sheet

Concept 2019 Q2 2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.616B $428.0M
YoY Change 744.85% -58.77%
Cash & Equivalents $3.576B $389.3M
Short-Term Investments $40.26M $38.73M
Other Short-Term Assets $161.0M $6.241B
YoY Change -97.42% 2982.52%
Inventory $96.82M $112.7M
Prepaid Expenses
Receivables $2.011B $1.842B
Other Receivables $525.0M $471.8M
Total Short-Term Assets $6.391B $9.085B
YoY Change -29.66% 125.79%
LONG-TERM ASSETS
Property, Plant & Equipment $3.405B $3.229B
YoY Change 5.46% -0.58%
Goodwill $6.865B $6.679B
YoY Change 2.8% -32.47%
Intangibles $120.6M $100.3M
YoY Change 20.27% -93.15%
Long-Term Investments $0.00 $0.00
YoY Change
Other Assets $97.44M $59.07M
YoY Change 64.96% -1.78%
Total Long-Term Assets $13.54B $10.35B
YoY Change 30.82% -32.43%
TOTAL ASSETS
Total Short-Term Assets $6.391B $9.085B
Total Long-Term Assets $13.54B $10.35B
Total Assets $19.93B $19.44B
YoY Change 2.55% 0.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $389.0M $542.3M
YoY Change -28.27% 23.32%
Accrued Expenses $1.001B $633.0M
YoY Change 58.14% -16.71%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $3.591B $1.769B
YoY Change 103.0% 871.98%
Total Short-Term Liabilities $5.707B $4.784B
YoY Change 19.3% 72.49%
LONG-TERM LIABILITIES
Long-Term Debt $5.378B $8.176B
YoY Change -34.22% -8.25%
Other Long-Term Liabilities $134.6M $418.1M
YoY Change -67.81% -19.73%
Total Long-Term Liabilities $134.6M $418.1M
YoY Change -67.81% -19.73%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.707B $4.784B
Total Long-Term Liabilities $134.6M $418.1M
Total Liabilities $14.50B $13.90B
YoY Change 4.3% 6.46%
SHAREHOLDERS EQUITY
Retained Earnings $3.206B $4.088B
YoY Change -21.58% -4.6%
Common Stock $989.2M $1.023B
YoY Change -3.3% -3.34%
Preferred Stock
YoY Change
Treasury Stock (at cost) $112.2M $809.9M
YoY Change -86.15% 249.59%
Treasury Stock Shares
Shareholders Equity $4.049B $4.279B
YoY Change
Total Liabilities & Shareholders Equity $19.93B $19.44B
YoY Change 2.55% 0.48%

Cashflow Statement

Concept 2019 Q2 2018 Q2
OPERATING ACTIVITIES
Net Income $273.6M $267.3M
YoY Change 2.35% 110.45%
Depreciation, Depletion And Amortization $152.3M $147.1M
YoY Change 3.54% -26.45%
Cash From Operating Activities $1.153B $350.0M
YoY Change 229.31% 147.18%
INVESTING ACTIVITIES
Capital Expenditures $175.0M $241.5M
YoY Change -27.53% 30.98%
Acquisitions
YoY Change
Other Investing Activities $3.778B $17.60M
YoY Change 21366.48% -104.22%
Cash From Investing Activities $3.603B -$224.0M
YoY Change -1708.53% -62.77%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.636B -83.40M
YoY Change 1861.15% -72.77%
NET CHANGE
Cash From Operating Activities 1.153B 350.0M
Cash From Investing Activities 3.603B -224.0M
Cash From Financing Activities -1.636B -83.40M
Net Change In Cash 3.120B 42.60M
YoY Change 7224.18% -105.56%
FREE CASH FLOW
Cash From Operating Activities $1.153B $350.0M
Capital Expenditures $175.0M $241.5M
Free Cash Flow $977.6M $108.5M
YoY Change 801.26% -353.4%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
dei Entity Central Index Key
EntityCentralIndexKey
0000927066
dva Percentage Change In Discount Rate Used To Evaluate Fair Value Of Reporting Unit For Goodwill Assessment
PercentageChangeInDiscountRateUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment
0.0100
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
450000000 shares
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
450000000 shares
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
166387307 shares
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
166532889 shares
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
166387307 shares
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
164472913 shares
CY2018Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
80566000 USD
CY2019Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
75283000 USD
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q4 us-gaap Property Plant And Equipment Owned Accumulated Depreciation
PropertyPlantAndEquipmentOwnedAccumulatedDepreciation
3524098000 USD
CY2019Q2 us-gaap Property Plant And Equipment Owned Accumulated Depreciation
PropertyPlantAndEquipmentOwnedAccumulatedDepreciation
3649978000 USD
us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
54.46
us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
2060000 shares
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
112189000 USD
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2019-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
1-14106
dei Entity Registrant Name
EntityRegistrantName
DAVITA INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
51-0354549
dei Entity Address Address Line1
EntityAddressAddressLine1
2000 16th Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Denver,
dei Entity Address State Or Province
EntityAddressStateOrProvince
CO
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
80202
dei City Area Code
CityAreaCode
720
dei Local Phone Number
LocalPhoneNumber
631-2100
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
DVA
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2019Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
160300000 shares
CY2019Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2734065000 USD
CY2018Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2718403000 USD
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
5369217000 USD
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
5309477000 USD
CY2019Q2 us-gaap Health Care Organization Patient Service Revenue Provisionfor Bad Debts
HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts
10249000 USD
CY2018Q2 us-gaap Health Care Organization Patient Service Revenue Provisionfor Bad Debts
HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts
49406000 USD
us-gaap Health Care Organization Patient Service Revenue Provisionfor Bad Debts
HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts
15712000 USD
us-gaap Health Care Organization Patient Service Revenue Provisionfor Bad Debts
HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts
23861000 USD
CY2019Q2 us-gaap Health Care Organization Patient Service Revenue Less Provision For Bad Debts
HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts
2723816000 USD
CY2018Q2 us-gaap Health Care Organization Patient Service Revenue Less Provision For Bad Debts
HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts
2668997000 USD
us-gaap Health Care Organization Patient Service Revenue Less Provision For Bad Debts
HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts
5353505000 USD
us-gaap Health Care Organization Patient Service Revenue Less Provision For Bad Debts
HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts
5285616000 USD
CY2019Q2 us-gaap Other Income
OtherIncome
118889000 USD
CY2018Q2 us-gaap Other Income
OtherIncome
217956000 USD
us-gaap Other Income
OtherIncome
232312000 USD
us-gaap Other Income
OtherIncome
450781000 USD
CY2019Q2 us-gaap Revenues
Revenues
2842705000 USD
CY2018Q2 us-gaap Revenues
Revenues
2886953000 USD
us-gaap Revenues
Revenues
5585817000 USD
us-gaap Revenues
Revenues
5736397000 USD
CY2019Q2 dva Patient Care Costs
PatientCareCosts
1957753000 USD
CY2018Q2 dva Patient Care Costs
PatientCareCosts
2069089000 USD
dva Patient Care Costs
PatientCareCosts
3922688000 USD
dva Patient Care Costs
PatientCareCosts
4104674000 USD
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
275338000 USD
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
264094000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
526151000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
530623000 USD
CY2019Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
152242000 USD
CY2018Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
147079000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
300770000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
289878000 USD
CY2019Q2 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 USD
CY2018Q2 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-2100000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-8100000 USD
CY2019Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
4514000 USD
CY2018Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
9795000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
7222000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
9950000 USD
CY2019Q2 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
0 USD
CY2018Q2 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
11245000 USD
us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
0 USD
us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
11245000 USD
CY2019Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
us-gaap Costs And Expenses
CostsAndExpenses
4783424000 USD
CY2018Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
3106000 USD
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
41037000 USD
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
3106000 USD
CY2019Q2 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
0 USD
CY2018Q2 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
33957000 USD
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
0 USD
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
33957000 USD
CY2019Q2 us-gaap Costs And Expenses
CostsAndExpenses
2380819000 USD
CY2018Q2 us-gaap Costs And Expenses
CostsAndExpenses
2448761000 USD
us-gaap Costs And Expenses
CostsAndExpenses
4887519000 USD
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
461886000 USD
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
438192000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
802393000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
848878000 USD
CY2019Q2 us-gaap Interest And Debt Expense
InterestAndDebtExpense
131666000 USD
CY2018Q2 us-gaap Interest And Debt Expense
InterestAndDebtExpense
119692000 USD
us-gaap Interest And Debt Expense
InterestAndDebtExpense
263185000 USD
us-gaap Interest And Debt Expense
InterestAndDebtExpense
233208000 USD
CY2019Q2 dva Debt Prepayment Charges
DebtPrepaymentCharges
12160000 USD
CY2018Q2 dva Debt Prepayment Charges
DebtPrepaymentCharges
0 USD
dva Debt Prepayment Charges
DebtPrepaymentCharges
12160000 USD
dva Debt Prepayment Charges
DebtPrepaymentCharges
0 USD
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5643000 USD
CY2018Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1994000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
12583000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6576000 USD
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
323703000 USD
CY2018Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
320494000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
539631000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
622246000 USD
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
75938000 USD
CY2018Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
83868000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
132684000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
154605000 USD
CY2019Q2 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
247765000 USD
CY2018Q2 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
236626000 USD
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
406947000 USD
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
467641000 USD
CY2019Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
79392000 USD
CY2018Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
69696000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
109697000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
63910000 USD
CY2019Q2 us-gaap Profit Loss
ProfitLoss
327157000 USD
CY2018Q2 us-gaap Profit Loss
ProfitLoss
306322000 USD
us-gaap Profit Loss
ProfitLoss
516644000 USD
us-gaap Profit Loss
ProfitLoss
531551000 USD
CY2019Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
53606000 USD
CY2018Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
39046000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
93804000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
85589000 USD
CY2019Q2 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
273551000 USD
CY2018Q2 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
267276000 USD
us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
422840000 USD
us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
445962000 USD
CY2019Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
1.17
CY2018Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
1.16
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
1.89
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
2.23
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.64
CY2018Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.56
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.54
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.54
CY2019Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
1.16
CY2018Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
1.15
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
1.89
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
2.19
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.64
CY2018Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.53
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.54
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.51
CY2019Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
166346041 shares
CY2018Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
171617238 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
166366886 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
175267270 shares
CY2019Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
166799525 shares
CY2018Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
174105884 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
166789978 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
177949934 shares
CY2019Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
194223000 USD
CY2018Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
199603000 USD
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
314477000 USD
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
390618000 USD
CY2019Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
79328000 USD
CY2018Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
67673000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
108363000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
55344000 USD
CY2019Q2 dva Income Loss From Continuing Operations Attributableto Parent Available To Common Stockholders Basic
IncomeLossFromContinuingOperationsAttributabletoParentAvailableToCommonStockholdersBasic
273551000 USD
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
267276000 USD
dva Income Loss From Continuing Operations Attributableto Parent Available To Common Stockholders Basic
IncomeLossFromContinuingOperationsAttributabletoParentAvailableToCommonStockholdersBasic
422840000 USD
us-gaap Net Income Loss
NetIncomeLoss
445962000 USD
CY2019Q2 us-gaap Profit Loss
ProfitLoss
327157000 USD
CY2018Q2 us-gaap Profit Loss
ProfitLoss
306322000 USD
us-gaap Profit Loss
ProfitLoss
516644000 USD
us-gaap Profit Loss
ProfitLoss
531551000 USD
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
-31000 USD
CY2018Q2 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
-268000 USD
us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
-611000 USD
us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
782000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax
-1606000 USD
CY2018Q2 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax
-1537000 USD
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax
-3212000 USD
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax
-3074000 USD
CY2019Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
12365000 USD
CY2018Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-50529000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-1288000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-30648000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
13940000 USD
CY2018Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-49260000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1313000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-26792000 USD
CY2019Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
341097000 USD
CY2018Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
257062000 USD
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
517957000 USD
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
504759000 USD
CY2019Q2 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
53606000 USD
CY2018Q2 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
39046000 USD
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
93804000 USD
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
85589000 USD
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
287491000 USD
CY2018Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
218016000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
424153000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
419170000 USD
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3575638000 USD
CY2018Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
118846000 USD
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
323038000 USD
CY2019Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
106772000 USD
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
92382000 USD
CY2019Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
5213000 USD
CY2018Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
2935000 USD
CY2019Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2010801000 USD
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1858608000 USD
CY2019Q2 us-gaap Inventory Net
InventoryNet
96819000 USD
CY2018Q4 us-gaap Inventory Net
InventoryNet
107381000 USD
CY2019Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
525004000 USD
CY2018Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
469796000 USD
CY2019Q2 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
15783000 USD
CY2018Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
68614000 USD
CY2019Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
54599000 USD
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
111840000 USD
CY2019Q2 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
0 USD
CY2018Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
5389565000 USD
CY2019Q2 us-gaap Assets Current
AssetsCurrent
6390629000 USD
CY2018Q4 us-gaap Assets Current
AssetsCurrent
8424159000 USD
CY2019Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3405315000 USD
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3393669000 USD
CY2019Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2790885000 USD
CY2018Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0 USD
CY2019Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
120574000 USD
CY2019Q2 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
225677000 USD
CY2018Q4 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
224611000 USD
CY2019Q2 us-gaap Long Term Investments
LongTermInvestments
35051000 USD
CY2018Q4 us-gaap Long Term Investments
LongTermInvestments
35424000 USD
CY2019Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
97443000 USD
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
71583000 USD
CY2019Q2 us-gaap Goodwill
Goodwill
6865386000 USD
CY2018Q4 us-gaap Goodwill
Goodwill
6841960000 USD
CY2019Q2 us-gaap Assets
Assets
19930960000 USD
CY2018Q4 us-gaap Assets
Assets
19110252000 USD
CY2019Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
388955000 USD
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
463270000 USD
CY2019Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
726011000 USD
CY2018Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
595850000 USD
CY2019Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
628022000 USD
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
658913000 USD
CY2019Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
372625000 USD
CY2018Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0 USD
CY2019Q2 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
3591331000 USD
CY2018Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
1929369000 USD
CY2019Q2 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
0 USD
CY2018Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
1243759000 USD
CY2019Q2 us-gaap Liabilities Current
LiabilitiesCurrent
5706944000 USD
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4891161000 USD
CY2019Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2689249000 USD
CY2018Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 USD
CY2019Q2 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
5377798000 USD
CY2018Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
8172847000 USD
CY2019Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
134605000 USD
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
450669000 USD
CY2019Q2 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
593562000 USD
CY2018Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
562536000 USD
CY2019Q2 us-gaap Liabilities
Liabilities
14502158000 USD
CY2018Q4 us-gaap Liabilities
Liabilities
14077213000 USD
CY2019Q2 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
1185733000 USD
CY2018Q4 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
1124641000 USD
CY2019Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
167000 USD
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
166000 USD
CY2019Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
989021000 USD
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
995006000 USD
CY2019Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
3205910000 USD
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
2743194000 USD
CY2019Q2 us-gaap Treasury Stock Value
TreasuryStockValue
112189000 USD
CY2018Q4 us-gaap Treasury Stock Value
TreasuryStockValue
0 USD
CY2019Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-33611000 USD
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-34924000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
4049298000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
3703442000 USD
CY2019Q2 us-gaap Minority Interest
MinorityInterest
193771000 USD
CY2018Q4 us-gaap Minority Interest
MinorityInterest
204956000 USD
CY2019Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
4243069000 USD
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3908398000 USD
CY2019Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19930960000 USD
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19110252000 USD
us-gaap Profit Loss
ProfitLoss
516644000 USD
us-gaap Profit Loss
ProfitLoss
531551000 USD
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
300770000 USD
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
289878000 USD
us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
41037000 USD
us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
14351000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
29045000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
19861000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
60706000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
56882000 USD
dva Adjustment Income Loss From Equity Method Investments
AdjustmentIncomeLossFromEquityMethodInvestments
-2631000 USD
dva Adjustment Income Loss From Equity Method Investments
AdjustmentIncomeLossFromEquityMethodInvestments
434000 USD
dva Gain Loss On Sale Of Business Including Activity From Discontinued Operations
GainLossOnSaleOfBusinessIncludingActivityFromDiscontinuedOperations
-23022000 USD
dva Gain Loss On Sale Of Business Including Activity From Discontinued Operations
GainLossOnSaleOfBusinessIncludingActivityFromDiscontinuedOperations
59053000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-25857000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-44337000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
288437000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
101746000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-11542000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-71632000 USD
dva Increase Decrease In Other Current Receivables And Other Current Assets
IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets
5142000 USD
dva Increase Decrease In Other Current Receivables And Other Current Assets
IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets
91685000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
410000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-3454000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-68887000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
35228000 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-88473000 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
23818000 USD
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
151780000 USD
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
58321000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
57551000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
24356000 USD
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-18121000 USD
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
3824000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
751115000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
924575000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
373918000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
473977000 USD
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
65970000 USD
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
89465000 USD
us-gaap Proceeds From Sales Of Business Affiliate And Productive Assets
ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
3851381000 USD
us-gaap Proceeds From Sales Of Business Affiliate And Productive Assets
ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
116241000 USD
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
4812000 USD
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
4195000 USD
us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
3322000 USD
us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
3726000 USD
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
5893000 USD
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
5662000 USD
us-gaap Proceeds From Sale And Maturity Of Held To Maturity Securities
ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
0 USD
us-gaap Proceeds From Sale And Maturity Of Held To Maturity Securities
ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
32628000 USD
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
6715000 USD
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
10241000 USD
us-gaap Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital
ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
155000 USD
us-gaap Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital
ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
3009000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3402692000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-424064000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
32367300000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
28128131000 USD
us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
33531409000 USD
us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
27556348000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
73078000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
805179000 USD
us-gaap Payments Of Distributions To Affiliates
PaymentsOfDistributionsToAffiliates
95714000 USD
us-gaap Payments Of Distributions To Affiliates
PaymentsOfDistributionsToAffiliates
94006000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
2107000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
3132000 USD
us-gaap Proceeds From Contributions From Affiliates
ProceedsFromContributionsFromAffiliates
31281000 USD
us-gaap Proceeds From Contributions From Affiliates
ProceedsFromContributionsFromAffiliates
31569000 USD
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
0 USD
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
15000 USD
us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
11040000 USD
us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
13223000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1310553000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-305909000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-77000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-3473000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2843177000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
191129000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
415420000 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
518920000 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3682410000 USD
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
480148000 USD
CY2019Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
29022000 USD
CY2018Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
52924000 USD
CY2019Q2 us-gaap Revenues
Revenues
2842705000 USD
CY2018Q2 us-gaap Revenues
Revenues
2886953000 USD
us-gaap Revenues
Revenues
5585817000 USD
us-gaap Revenues
Revenues
5736397000 USD
CY2019Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
194223000 USD
CY2018Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
199603000 USD
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
314477000 USD
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
390618000 USD
CY2019Q2 us-gaap Minority Interest Change In Redemption Value
MinorityInterestChangeInRedemptionValue
0 USD
CY2018Q2 us-gaap Minority Interest Change In Redemption Value
MinorityInterestChangeInRedemptionValue
-98000 USD
us-gaap Minority Interest Change In Redemption Value
MinorityInterestChangeInRedemptionValue
0 USD
us-gaap Minority Interest Change In Redemption Value
MinorityInterestChangeInRedemptionValue
-98000 USD
CY2019Q2 dva Income Loss From Continuing Operations Available To Common Stockholders Basic
IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic
194223000 USD
CY2018Q2 dva Income Loss From Continuing Operations Available To Common Stockholders Basic
IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic
199505000 USD
dva Income Loss From Continuing Operations Available To Common Stockholders Basic
IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic
314477000 USD
dva Income Loss From Continuing Operations Available To Common Stockholders Basic
IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic
390520000 USD
CY2019Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
79328000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.65
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.31
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.64
CY2018Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.56
CY2019Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
454000 shares
CY2018Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
295000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
423000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
489000 shares
CY2019Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
166800000 shares
CY2018Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
174106000 shares
CY2018Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
67673000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
108363000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
55344000 USD
CY2019Q2 dva Income Loss From Continuing Operations Attributableto Parent Available To Common Stockholders Basic
IncomeLossFromContinuingOperationsAttributabletoParentAvailableToCommonStockholdersBasic
273551000 USD
CY2018Q2 dva Income Loss From Continuing Operations Attributableto Parent Available To Common Stockholders Basic
IncomeLossFromContinuingOperationsAttributabletoParentAvailableToCommonStockholdersBasic
267178000 USD
dva Income Loss From Continuing Operations Attributableto Parent Available To Common Stockholders Basic
IncomeLossFromContinuingOperationsAttributabletoParentAvailableToCommonStockholdersBasic
422840000 USD
dva Income Loss From Continuing Operations Attributableto Parent Available To Common Stockholders Basic
IncomeLossFromContinuingOperationsAttributabletoParentAvailableToCommonStockholdersBasic
445864000 USD
CY2019Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
166346000 shares
CY2018Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
173811000 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
166367000 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
177461000 shares
CY2019Q2 us-gaap Weighted Average Number Of Shares Contingently Issuable
WeightedAverageNumberOfSharesContingentlyIssuable
0 shares
CY2018Q2 us-gaap Weighted Average Number Of Shares Contingently Issuable
WeightedAverageNumberOfSharesContingentlyIssuable
2194000 shares
us-gaap Weighted Average Number Of Shares Contingently Issuable
WeightedAverageNumberOfSharesContingentlyIssuable
0 shares
us-gaap Weighted Average Number Of Shares Contingently Issuable
WeightedAverageNumberOfSharesContingentlyIssuable
2194000 shares
CY2019Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
166346000 shares
CY2018Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
171617000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
166367000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
175267000 shares
CY2019Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
1.17
CY2018Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
1.16
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
1.89
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
2.23
CY2019Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.47
CY2018Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.40
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.54
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.54
CY2019Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
166346000 shares
CY2018Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
173811000 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
166367000 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
177461000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
166790000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
177950000 shares
CY2019Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
1.16
CY2018Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
1.15
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
1.89
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
2.19
CY2019Q2 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
0.48
CY2018Q2 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
0.38
us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
0.65
us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
0.32
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.64
CY2018Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.53
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.54
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.51
CY2019Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5797000 shares
CY2018Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6227000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5974000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4840000 shares
CY2019Q2 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
3113000 USD
CY2019Q2 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
37151000 USD
CY2019Q2 us-gaap Marketable Securities
MarketableSecurities
40264000 USD
CY2018Q4 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
2235000 USD
CY2018Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
36124000 USD
CY2018Q4 us-gaap Marketable Securities
MarketableSecurities
38359000 USD
CY2019Q2 us-gaap Held To Maturity Securities Current
HeldToMaturitySecuritiesCurrent
3113000 USD
CY2019Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
5213000 USD
CY2018Q4 us-gaap Held To Maturity Securities Current
HeldToMaturitySecuritiesCurrent
2235000 USD
CY2018Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
2935000 USD
CY2019Q2 us-gaap Held To Maturity Securities Noncurrent
HeldToMaturitySecuritiesNoncurrent
0 USD
CY2019Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
35051000 USD
CY2018Q4 us-gaap Held To Maturity Securities Noncurrent
HeldToMaturitySecuritiesNoncurrent
0 USD
CY2018Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
35424000 USD
CY2019Q2 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
3113000 USD
CY2019Q2 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
37151000 USD
CY2019Q2 us-gaap Marketable Securities
MarketableSecurities
40264000 USD
CY2018Q4 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
2235000 USD
CY2018Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
36124000 USD
CY2018Q4 us-gaap Marketable Securities
MarketableSecurities
38359000 USD
CY2019Q2 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
225677000 USD
CY2018Q4 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
224611000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
7222000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
9950000 USD
dva Valuation Adjustment
ValuationAdjustment
1938000 USD
dva Valuation Adjustment
ValuationAdjustment
0 USD
CY2017Q4 us-gaap Goodwill
Goodwill
6610279000 USD
CY2018 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
278348000 USD
CY2018 us-gaap Goodwill Written Off Related To Sale Of Business Unit
GoodwillWrittenOffRelatedToSaleOfBusinessUnit
15497000 USD
CY2018 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
3106000 USD
CY2018 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-28064000 USD
CY2018Q4 us-gaap Goodwill
Goodwill
6841960000 USD
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
66614000 USD
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
41037000 USD
us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-2151000 USD
CY2019Q2 us-gaap Goodwill
Goodwill
6865386000 USD
CY2019Q2 us-gaap Goodwill Gross
GoodwillGross
6933984000 USD
CY2019Q2 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
68598000 USD
CY2019Q2 us-gaap Goodwill
Goodwill
6865386000 USD
dva Percentage Change In Operating Income Used To Evaluate Fair Value Of Reporting Unit For Goodwill Assessment
PercentageChangeInOperatingIncomeUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment
0.03
CY2019Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
49877000 USD
CY2019Q2 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
47034000 USD
us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
9495000 USD
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
40382000 USD
CY2019Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
10642000 USD
CY2018Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
9019000 USD
CY2019Q2 dva Acquisition Obligations And Other Notes Payable
AcquisitionObligationsAndOtherNotesPayable
184170000 USD
CY2018Q4 dva Acquisition Obligations And Other Notes Payable
AcquisitionObligationsAndOtherNotesPayable
183979000 USD
CY2019Q2 dva Acquisition Obligations And Other Notes Payable
AcquisitionObligationsAndOtherNotesPayable
184170000 USD
CY2019Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
277580000 USD
CY2018Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
282737000 USD
CY2019Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
277580000 USD
CY2019Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
9003631000 USD
CY2018Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10154216000 USD
CY2019Q2 dva Discount And Deferred Finance Costs
DiscountAndDeferredFinanceCosts
34502000 USD
CY2018Q4 dva Discount And Deferred Finance Costs
DiscountAndDeferredFinanceCosts
52000000 USD
CY2019Q2 us-gaap Long Term Debt And Capital Lease Obligations Including Current Maturities
LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
8969129000 USD
CY2018Q4 us-gaap Long Term Debt And Capital Lease Obligations Including Current Maturities
LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
10102216000 USD
CY2019Q2 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
3591331000 USD
CY2018Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
1929369000 USD
CY2019Q2 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
5377798000 USD
CY2018Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
8172847000 USD
CY2019Q2 dva Long Term Debt Maturity Extension Term
LongTermDebtMaturityExtensionTerm
P6M
us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2019-12-24
CY2019Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
3564562000 USD
CY2019Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
53182000 USD
CY2019Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
533377000 USD
CY2019Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
1292979000 USD
CY2019Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
54372000 USD
CY2019Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
1785765000 USD
CY2019Q2 us-gaap Long Term Debt Maturities Repayments Of Principal After Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
1719394000 USD
CY2019Q2 us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.0517
us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.0516
CY2019Q2 us-gaap Longterm Debt Weighted Average Interest Rate
LongtermDebtWeightedAverageInterestRate
0.0530
CY2019Q2 us-gaap Long Term Debt Percentage Bearing Fixed Interest Rate
LongTermDebtPercentageBearingFixedInterestRate
0.5410
CY2019Q2 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
72763000 USD
CY2019Q2 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
246261000 USD
CY2018Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
367164000 USD
CY2019Q2 dva Finance Lease Accumulated Depreciation
FinanceLeaseAccumulatedDepreciation
15525000 USD
CY2018Q4 dva Finance Lease Accumulated Depreciation
FinanceLeaseAccumulatedDepreciation
131971000 USD
CY2019Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
130946000 USD
us-gaap Operating Lease Expense
OperatingLeaseExpense
259056000 USD
CY2019Q2 us-gaap Variable Lease Cost
VariableLeaseCost
29907000 USD
us-gaap Variable Lease Cost
VariableLeaseCost
58478000 USD
CY2019Q2 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
5703000 USD
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
11529000 USD
CY2019Q2 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
3715000 USD
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
7490000 USD
CY2019Q2 us-gaap Lease Cost
LeaseCost
170271000 USD
us-gaap Lease Cost
LeaseCost
336553000 USD
CY2019Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y1M6D
CY2019Q2 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P10Y7M6D
CY2019Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.042
us-gaap Sale And Leaseback Transaction Gain Loss Net
SaleAndLeasebackTransactionGainLossNet
10336000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
309115000 USD
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
10585000 USD
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
16910000 USD
dva Net Operating Lease Assets Obtained In Exchange For Lease Liabilities
NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities
195771000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
259928000 USD
CY2019Q2 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
16493000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
490779000 USD
CY2019Q2 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
37805000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
463495000 USD
CY2019Q2 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
33317000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
426182000 USD
CY2019Q2 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
33599000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
380070000 USD
CY2019Q2 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
33709000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
326541000 USD
CY2019Q2 us-gaap Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
33723000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
1375473000 USD
CY2019Q2 us-gaap Finance Lease Liability Payments Due After Year Five
FinanceLeaseLiabilityPaymentsDueAfterYearFive
175202000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3722468000 USD
CY2019Q2 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
363848000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
660594000 USD
CY2019Q2 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
86268000 USD
CY2019Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
3061874000 USD
CY2019Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
277580000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
483488000 USD
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
36754000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
462154000 USD
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
41044000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
432950000 USD
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
34026000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
395462000 USD
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due In Four Years
CapitalLeasesFutureMinimumPaymentsDueInFourYears
33690000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
349649000 USD
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due In Five Years
CapitalLeasesFutureMinimumPaymentsDueInFiveYears
33845000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
1589949000 USD
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due Thereafter
CapitalLeasesFutureMinimumPaymentsDueThereafter
194611000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
3713652000 USD
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
373970000 USD
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Interest Included In Payments
CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments
91233000 USD
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments
CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments
282737000 USD
us-gaap Loss Contingency Disclosures
LossContingencyDisclosures
<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Contingencies</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The majority of the Company’s revenues are from government programs and may be subject to adjustment as a result of: (i) examination by government agencies or contractors, for which the resolution of any matters raised may take extended periods of time to finalize; (ii) differing interpretations of government regulations by different Medicare contractors or regulatory authorities; (iii) differing opinions regarding a patient’s medical diagnosis or the medical necessity of services provided; and (iv) retroactive applications or interpretations of governmental requirements. In addition, the Company’s revenues from commercial payors may be subject to adjustment as a result of potential claims for refunds, as a result of government actions or as a result of other claims by commercial payors.</span></div><div style="line-height:120%;padding-top:12px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company operates in a highly regulated industry and is a party to various lawsuits, demands, claims, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</span><span style="font-family:inherit;font-size:10pt;"> suits, governmental investigations and audits (including, without limitation, investigations or other actions resulting from its obligation to self-report suspected violations of law) and other legal proceedings. The Company records accruals for certain legal proceedings and regulatory matters to the extent that the Company determines an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. As of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company’s total recorded accruals with respect to legal proceedings and regulatory matters, net of anticipated third party recoveries, were immaterial. While these accruals reflect the Company’s best estimate of the probable loss for those matters as of the dates of those accruals, the recorded amounts may differ materially from the actual amount of the losses for those matters, and any anticipated third party recoveries for any such losses may not ultimately be recoverable. Additionally, in some cases, no estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made because of the inherently unpredictable nature of legal proceedings and regulatory matters, which also may be impacted by various factors, including, without limitation, that they may involve indeterminate claims for monetary damages or may involve fines, penalties or non-monetary remedies; present novel legal theories or legal uncertainties; involve disputed facts; represent a shift in regulatory policy; are in the early stages of the </span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">proceedings; or may result in a change of business practices. Further, there may be various levels of judicial review available to the Company in connection with any such proceeding.</span></div><div style="line-height:120%;padding-top:12px;text-indent:37px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a description of certain lawsuits, claims, governmental investigations and audits and other legal proceedings to which the Company is subject.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Governmental Inquiries and Certain Related Proceedings</span></div><div style="line-height:120%;padding-top:12px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">2016 U.S. Attorney Texas Investigation</span><span style="font-family:inherit;font-size:10pt;">: In early February 2016, the Company announced that its pharmacy services' wholly-owned subsidiary, DaVita Rx, LLC (DaVita Rx), received a Civil Investigative Demand (CID) from the U.S. Attorney’s Office, Northern District of Texas. The government is conducting a federal False Claims Act (FCA) investigation concerning allegations that DaVita Rx presented or caused to be presented false claims for payment to the government for prescription medications, as well as an investigation into the Company’s relationships with pharmaceutical manufacturers. The CID covers the period from January 1, 2006 through the present. In connection with the Company’s ongoing efforts working with the government, the Company learned that a </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</span><span style="font-family:inherit;font-size:10pt;"> complaint had been filed covering some of the issues in the CID and practices that had been identified by the Company in a self-disclosure filed with the Office of Inspector General (OIG) for the U.S. Department of Health and Human Services (HHS) in February 2016. In December 2017, the Company finalized and executed a settlement agreement with the government and relators in the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</span><span style="font-family:inherit;font-size:10pt;"> matter that included total monetary consideration of </span><span style="font-family:inherit;font-size:10pt;"><span>$63,700</span></span><span style="font-family:inherit;font-size:10pt;">, as previously disclosed, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$41,500</span></span><span style="font-family:inherit;font-size:10pt;"> was an incremental cash payment and </span><span style="font-family:inherit;font-size:10pt;"><span>$22,200</span></span><span style="font-family:inherit;font-size:10pt;"> was for amounts previously refunded, and all of which was previously accrued. The government’s investigation into certain of the Company's relationships with pharmaceutical manufacturers is ongoing, and in July 2018 the OIG served the Company with a subpoena seeking additional documents and information relating to those relationships. The Company is continuing to cooperate with the government in this investigation.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">2017 U.S. Attorney Massachusetts Investigation</span><span style="font-family:inherit;font-size:10pt;">: In January 2017, the Company was served with an administrative subpoena for records by the U.S. Attorney’s Office, District of Massachusetts, relating to an investigation into possible federal health care offenses. The subpoena covered the period from January 1, 2007 to the present, and sought documents relevant to charitable patient assistance organizations, particularly the American Kidney Fund, including documents related to efforts to provide patients with information concerning the availability of charitable assistance. The Department of Justice notified the Court on July 23, 2019 of its decision to elect not to intervene in the matter of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">U.S. ex rel. David Gonzalez v. DaVita Healthcare Partners, et al</span><span style="font-family:inherit;font-size:10pt;">. The complaint then was unsealed in the US. District Court, District of Massachusetts by order entered on August 1, 2019. The Department of Justice has confirmed that the complaint, which alleges violations of the federal False Claims Act and various state false claims acts, was the basis of its investigation initiated in January 2017. The Company has not been served with the complaint.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">2017 U.S. Attorney Colorado Investigation</span><span style="font-family:inherit;font-size:10pt;">: In November 2017, the U.S. Attorney’s Office, District of Colorado informed the Company of an investigation it was conducting into possible federal healthcare offenses involving DaVita Kidney Care, as well as several of the Company’s wholly-owned subsidiaries. The matter currently includes an investigation into DaVita Rx, DaVita Laboratory Services, Inc. (DaVita Labs), and RMS Lifeline Inc. (Lifeline). In each of August 2018 and May 2019, the Company received a CID pursuant to the FCA from the U.S. Attorney's Office relating to this investigation. The Company is continuing to cooperate with the government in this investigation. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">2018 U.S. Attorney Florida Investigation</span><span style="font-family:inherit;font-size:10pt;">: In March 2018, DaVita Labs received two CIDs from the U.S. Attorney’s Office, Middle District of Florida that were identical in nature but directed to the two different labs. According to the face of the CIDs, the U.S. Attorney’s Office is conducting an investigation as to whether the Company’s subsidiary submitted claims for blood, urine, and fecal testing, where there were insufficient test validation or stability studies to ensure accurate results, in violation of the FCA. In October 2018, DaVita Labs received a subpoena from the OIG in connection with this matter requesting certain patient records linked to clinical laboratory tests. The Company is continuing to cooperate with the government in this investigation.</span></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">* * *</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Although the Company cannot predict whether or when proceedings might be initiated or when these matters may be resolved (other than as may be described above), it is not unusual for inquiries such as these to continue for a considerable period of time through the various phases of document and witness requests and on-going discussions with regulators and to develop over the course of time. In addition to the inquiries and proceedings specifically identified above, the Company frequently is subject to other inquiries by state or federal government agencies and/or private civil </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</span><span style="font-family:inherit;font-size:10pt;"> complaints filed by </span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">relators. Negative findings or terms and conditions that the Company might agree to accept as part of a negotiated resolution of pending or future government inquiries or relator proceedings could result in, among other things, substantial financial penalties or awards against the Company, substantial payments made by the Company, harm to the Company’s reputation, required changes to the Company’s business practices, exclusion from future participation in the Medicare, Medicaid and other federal health care programs and, if criminal proceedings were initiated against the Company, members of its board of directors or management, possible criminal penalties, any of which could have a material adverse effect on the Company.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Shareholder and Derivative Claims</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Peace Officers’ Annuity and Benefit Fund of Georgia Securities Class Action Civil Suit</span><span style="font-family:inherit;font-size:10pt;">: On February 1, 2017, the Peace Officers’ Annuity and Benefit Fund of Georgia filed a putative federal securities class action complaint in the U.S. District Court for the District of Colorado against the Company and certain executives. The complaint covers the time period of August 2015 to October 2016 and alleges, generally, that the Company and its executives violated</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">federal securities laws concerning the Company’s financial results and revenue derived from patients who received charitable premium assistance from an industry-funded non-profit organization. The complaint further alleges that the process by which patients obtained commercial insurance and received charitable premium assistance was improper and "created a false impression of DaVita’s business and operational status and future growth prospects." In November 2017, the court appointed the lead plaintiff and an amended complaint was filed on January 12, 2018. On March 27, 2018, the Company and various individual defendants filed a motion to dismiss. On March 28, 2019, the U.S. District Court for the District of Colorado denied the motion to dismiss. The Company answered the complaint on May 28, 2019. The Company disputes these allegations and intends to defend this action accordingly.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">In re DaVita Inc. Stockholder Derivative Litigation</span><span style="font-family:inherit;font-size:10pt;">: On August 15, 2017, the U.S. District Court for the District of Delaware consolidated </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> previously disclosed shareholder derivative lawsuits: the Blackburn Shareholder action filed on February 10, 2017, the Gabilondo Shareholder action filed on May 30, 2017, and the City of Warren Police and Fire Retirement System Shareholder action filed on June 9, 2017. The complaint covers the time period from 2015 to present and alleges, generally, breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, corporate waste, and misrepresentations and/or failures to disclose certain information in violation of the federal securities laws in connection with an alleged practice to direct patients with government-subsidized health insurance into private health insurance plans to maximize the Company’s profits. An amended complaint was filed in September 2017, and on December 18, 2017, the Company filed a motion to dismiss and a motion to stay proceedings in the alternative. On April 25, 2019, the court denied the Company's motion to dismiss. The Company answered the complaint on May 28, 2019. The Company disputes these allegations and intends to defend this action accordingly. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Proceedings</span></div><div style="line-height:120%;padding-top:12px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to the foregoing, from time to time the Company is subject to other lawsuits, demands, claims, governmental investigations and audits and legal proceedings that arise due to the nature of its business, including, without limitation, contractual disputes, such as with payors, suppliers and others, employee-related matters and professional and general liability claims. From time to time, the Company also initiates litigation or other legal proceedings as a plaintiff arising out of contracts or other matters.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Resolved Matters</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">2017 U.S. Attorney Florida Investigation</span><span style="font-family:inherit;font-size:10pt;">: In November 2017, the U.S. Attorney’s Office, Southern District of Florida, informed the Company of an investigation it was conducting into possible federal healthcare offenses involving the Company's wholly-owned subsidiary, Lifeline. The U.S. Attorney's Office, Southern District of Florida notified the court on April 4, 2019 of its decision to elect not to intervene in the matter of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Gabriel Valle, M.D., et al, v. RMS Lifeline, Inc., et al</span><span style="font-family:inherit;font-size:10pt;">. The complaint then was unsealed in the U.S. District Court, Southern District of Florida by order dated April 5, 2019. The U.S. Attorney's Office confirmed that the complaint, which alleges violations of the FCA, was the basis of its investigation initiated in November 2017. On July 16, 2019, the private party relators filed a Notice of Voluntary Dismissal of the matter, and the court dismissed the lawsuit without prejudice and closed the case.</span></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">* * *</span></div><div style="line-height:120%;padding-top:12px;text-indent:37px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other than as may be described above, the Company cannot predict the ultimate outcomes of the various legal proceedings and regulatory matters to which the Company is or may be subject from time to time, including those described in </span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">this Note </span><span style="font-family:inherit;font-size:10pt;">11</span><span style="font-family:inherit;font-size:10pt;"> to these condensed consolidated financial statements, or the timing of their resolution or the ultimate losses or impact of developments in those matters, which could have a material adverse effect on the Company’s revenues, earnings and cash flows. Further, any legal proceedings or regulatory matters involving the Company, whether meritorious or not, are time consuming, and often require management’s attention and result in significant legal expense, and may result in the diversion of significant operational resources, or otherwise harm the Company’s business, results of operations, financial condition, cash flows or reputation.</span></div>
dva Longterm Incentive Program Compensation Cost
LongtermIncentiveProgramCompensationCost
41054000 USD
dva Longterm Incentive Program Compensation Cost
LongtermIncentiveProgramCompensationCost
31301000 USD
dva Employee Service Share Based Compensation Estimated Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense
3835000 USD
dva Employee Service Share Based Compensation Estimated Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense
3941000 USD
CY2019Q2 dva Longterm Incentive Program Awards Compensation Cost Not Yet Recognized Net
LongtermIncentiveProgramAwardsCompensationCostNotYetRecognizedNet
169602000 USD
CY2019Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
155951000 USD
dva Longterm Incentive Program Awards Compensation Cost Not Yet Recognized Period For Recognition
LongtermIncentiveProgramAwardsCompensationCostNotYetRecognizedPeriodForRecognition
P0Y9M18D
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y8M12D
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
2675000 USD
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
7671000 USD
CY2019Q2 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
2060000 shares
CY2019Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
112189000 USD
CY2019Q2 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
54.46
us-gaap Business Combination Consideration Transferred Liabilities Incurred
BusinessCombinationConsiderationTransferredLiabilitiesIncurred
12484000 USD
dva Business Combination Contingent Consideration Acquisitions
BusinessCombinationContingentConsiderationAcquisitions
25875000 USD
CY2018Q4 us-gaap Business Combination Contingent Consideration Arrangements Range Of Outcomes Value High
BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
2608000 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-12440000 USD
dva Business Combination Contingent Consideration Acquisitions Fair Value Remeasurement Gain Loss
BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss
101000 USD
dva Business Combination Contingent Consideration Acquisitions Earnouts Payments
BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments
217000 USD
CY2019Q2 us-gaap Business Combination Contingent Consideration Arrangements Range Of Outcomes Value High
BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
14730000 USD
CY2019Q2 us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
4465476000 USD
CY2019Q2 us-gaap Proceeds From Divestiture Of Businesses Net Of Cash Divested
ProceedsFromDivestitureOfBusinessesNetOfCashDivested
3824509000 USD
CY2019Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
79392000 USD
CY2018Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
69696000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
109697000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
63910000 USD
CY2019Q2 us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
103848000 USD
CY2018Q2 us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
112683000 USD
CY2019Q2 us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
-43442000 USD
CY2018Q2 us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
-20982000 USD
CY2019Q2 us-gaap Variable Interest Entity Consolidated Carrying Amount Assets
VariableInterestEntityConsolidatedCarryingAmountAssets
390935000 USD
CY2019Q2 us-gaap Variable Interest Entity Consolidated Carrying Amount Liabilities
VariableInterestEntityConsolidatedCarryingAmountLiabilities
277638000 USD
CY2019Q2 us-gaap Revenues
Revenues
2842705000 USD
CY2018Q2 us-gaap Revenues
Revenues
2886953000 USD
us-gaap Revenues
Revenues
5585817000 USD
us-gaap Revenues
Revenues
5736397000 USD
CY2019Q2 dva Segment Reporting Information Corporate Expenses
SegmentReportingInformationCorporateExpenses
22021000 USD
CY2018Q2 dva Segment Reporting Information Corporate Expenses
SegmentReportingInformationCorporateExpenses
14066000 USD
dva Segment Reporting Information Corporate Expenses
SegmentReportingInformationCorporateExpenses
40866000 USD
dva Segment Reporting Information Corporate Expenses
SegmentReportingInformationCorporateExpenses
29769000 USD
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
461886000 USD
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
438192000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
802393000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
848878000 USD
CY2018Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
147079000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
300770000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
289878000 USD
CY2019Q2 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
175040000 USD
CY2018Q2 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
241534000 USD
CY2019Q2 us-gaap Interest And Debt Expense
InterestAndDebtExpense
131666000 USD
CY2018Q2 us-gaap Interest And Debt Expense
InterestAndDebtExpense
119692000 USD
us-gaap Interest And Debt Expense
InterestAndDebtExpense
263185000 USD
us-gaap Interest And Debt Expense
InterestAndDebtExpense
233208000 USD
CY2019Q2 dva Debt Prepayment Charges
DebtPrepaymentCharges
12160000 USD
CY2018Q2 dva Debt Prepayment Charges
DebtPrepaymentCharges
0 USD
dva Debt Prepayment Charges
DebtPrepaymentCharges
12160000 USD
dva Debt Prepayment Charges
DebtPrepaymentCharges
0 USD
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5643000 USD
CY2018Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1994000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
12583000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6576000 USD
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
323703000 USD
CY2018Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
320494000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
539631000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
622246000 USD
CY2019Q2 us-gaap Assets
Assets
19930960000 USD
CY2018Q4 us-gaap Assets
Assets
19110252000 USD
CY2019Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
152242000 USD
us-gaap Revenues
Revenues
5585817000 USD
us-gaap Costs And Expenses
CostsAndExpenses
4783424000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
802393000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
373918000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
473977000 USD
CY2019Q2 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
273551000 USD
CY2018Q2 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
267276000 USD
us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
422840000 USD
us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
445962000 USD
CY2019Q2 us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Sale Of Interest By Parent
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesSaleOfInterestByParent
0 USD
CY2018Q2 us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Sale Of Interest By Parent
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesSaleOfInterestByParent
3000 USD
us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Sale Of Interest By Parent
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesSaleOfInterestByParent
0 USD
us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Sale Of Interest By Parent
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesSaleOfInterestByParent
79000 USD
CY2019Q2 dva Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Purchase Or Sale Of Interest By Parent
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOrSaleOfInterestByParent
13140000 USD
CY2018Q2 us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Purchase Of Interest By Parent
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent
10203000 USD
dva Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Purchase Or Sale Of Interest By Parent
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOrSaleOfInterestByParent
10934000 USD
us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Purchase Of Interest By Parent
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent
12197000 USD
CY2019Q2 us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Net
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNet
13140000 USD
CY2018Q2 us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Net
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNet
-10200000 USD
us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Net
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNet
10934000 USD
us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Net
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNet
-12118000 USD
CY2019Q2 us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Change Due To Net Income Attributable To Parent And Effects Of Changes Net
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet
286691000 USD
CY2018Q2 us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Change Due To Net Income Attributable To Parent And Effects Of Changes Net
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet
257076000 USD
us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Change Due To Net Income Attributable To Parent And Effects Of Changes Net
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet
433774000 USD
us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Change Due To Net Income Attributable To Parent And Effects Of Changes Net
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet
433844000 USD
us-gaap Description Of New Accounting Pronouncements Not Yet Adopted
DescriptionOfNewAccountingPronouncementsNotYetAdopted
<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">New accounting standards</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</span><span style="font-family:inherit;font-size:10pt;">. The amendments in Topic 842 revise the accounting related to lessee accounting. Under the new guidance, lessees are required to recognize a lease liability and a right-of-use asset for substantially all leases with lease terms in excess of twelve months. The new lease guidance also simplifies the accounting for sale and leaseback transactions primarily because lessees must recognize lease assets and lease liabilities. The Company adopted Topic 842 beginning on January 1, 2019 through a modified retrospective approach for leases existing at the adoption date with a cumulative effect adjustment. The Company elected to apply the package of practical expedients to not recast prior conclusions related to contracts containing leases, lease classification and initial direct costs. Adoption of the new standard </span></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">resulted in the recording of operating right-of-use assets of </span><span style="font-family:inherit;font-size:10pt;"><span>$2,783,784</span></span><span style="font-family:inherit;font-size:10pt;">, operating lease liabilities of </span><span style="font-family:inherit;font-size:10pt;"><span>$3,001,354</span></span><span style="font-family:inherit;font-size:10pt;"> and an adjustment to retained earnings of </span><span style="font-family:inherit;font-size:10pt;"><span>$39,876</span></span><span style="font-family:inherit;font-size:10pt;">, primarily related to deferred gains on prior sale leaseback transactions as of January 1, 2019. The standard did not materially impact the Company's consolidated net earnings and had </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> impact on cash flows. See Note </span><span style="font-family:inherit;font-size:10pt;">10</span><span style="font-family:inherit;font-size:10pt;"> to these condensed consolidated financial statements for further details.</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. </span><span style="font-family:inherit;font-size:10pt;">The amendments in this ASU change the approach for recognizing credit losses on financial assets from the incurred loss methodology in current GAAP to a methodology that reflects current expected credit losses, which requires consideration of a broader range of reasonable and supportable information to inform those credit loss estimates. The current incurred loss model delays recognition of credit losses until it is probable that a loss has been incurred, while this ASU’s new current expected credit loss model requires estimation of credit losses expected over the life of the financial asset or group of similar financial assets. The amendments in this ASU are effective for the Company on January 1, 2020 and are to be applied on a modified-retrospective approach. The Company is still evaluating certain aspects of this ASU as well as the impacts it may have on its consolidated financial statements when adopted on January 1, 2020.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2017, the FASB issued ASU No. 2017-12, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities. </span><span style="font-family:inherit;font-size:10pt;">The amendments in this ASU better align an entity’s risk management activities and financial reporting for hedging relationships through changes to both the designation and measurement guidance for qualifying hedging relationships and the presentation of hedge results. The amendments in this ASU were effective for the Company on January 1, 2019 and are to be applied prospectively. The adoption of this ASU did not have a material impact on the Company’s consolidated financial statements when adopted on January 1, 2019.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU No. 2018-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurement (Topic 820): Disclosure Framework -Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="font-family:inherit;font-size:10pt;">. The applicable amendments in this ASU remove requirements for disclosures concerning transfers between fair value measurement levels 1, 2 and 3 and disclosures concerning valuation processes for level 3 fair value measurements. The applicable amendments in this ASU also add a requirement to separately disclose the changes in unrealized gains and losses included in other comprehensive income for the reporting period for level 3 items measured at fair value on a recurring basis, and require disclosure of the range and weighted average of significant unobservable inputs used to develop level 3 fair value measurements. The amendments in this ASU are effective for the Company beginning on January 1, 2020 and its new requirements are to be applied on a prospective basis. The adoption of this ASU is not expected to have a material impact on the Company’s consolidated financial statements.</span></div>
CY2019Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2734065000 USD
CY2019Q2 us-gaap Health Care Organization Patient Service Revenue Provisionfor Bad Debts
HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts
10249000 USD
CY2019Q2 us-gaap Health Care Organization Patient Service Revenue Less Provision For Bad Debts
HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts
2723816000 USD
CY2019Q2 us-gaap Other Income
OtherIncome
118889000 USD
CY2019Q2 us-gaap Revenues
Revenues
2842705000 USD
CY2019Q2 us-gaap Costs And Expenses
CostsAndExpenses
2380819000 USD
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
461886000 USD
CY2019Q2 dva Debt Expense Including Debt Refinancing Charges
DebtExpenseIncludingDebtRefinancingCharges
143826000 USD
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5643000 USD
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
75938000 USD
CY2019Q2 dva Equity In Earnings Loss Of Consolidated Affiliates
EquityInEarningsLossOfConsolidatedAffiliates
0 USD
CY2019Q2 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
247765000 USD
CY2019Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
79392000 USD
CY2019Q2 us-gaap Profit Loss
ProfitLoss
327157000 USD
CY2019Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
53606000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
273551000 USD
CY2018Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2718403000 USD
CY2018Q2 us-gaap Health Care Organization Patient Service Revenue Provisionfor Bad Debts
HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts
49406000 USD
CY2018Q2 us-gaap Health Care Organization Patient Service Revenue Less Provision For Bad Debts
HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts
2668997000 USD
CY2018Q2 us-gaap Other Income
OtherIncome
217956000 USD
CY2018Q2 us-gaap Revenues
Revenues
2886953000 USD
CY2018Q2 us-gaap Costs And Expenses
CostsAndExpenses
2448761000 USD
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
438192000 USD
CY2018Q2 dva Debt Expense Including Debt Refinancing Charges
DebtExpenseIncludingDebtRefinancingCharges
119692000 USD
CY2018Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1994000 USD
CY2018Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
83868000 USD
CY2018Q2 dva Equity In Earnings Loss Of Consolidated Affiliates
EquityInEarningsLossOfConsolidatedAffiliates
0 USD
CY2018Q2 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
236626000 USD
CY2018Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
69696000 USD
CY2018Q2 us-gaap Profit Loss
ProfitLoss
306322000 USD
CY2018Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
39046000 USD
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
267276000 USD
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
5369217000 USD
us-gaap Health Care Organization Patient Service Revenue Provisionfor Bad Debts
HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts
15712000 USD
us-gaap Health Care Organization Patient Service Revenue Less Provision For Bad Debts
HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts
5353505000 USD
us-gaap Other Income
OtherIncome
232312000 USD
CY2019Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
341097000 USD
CY2019Q2 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
53606000 USD
dva Debt Expense Including Debt Refinancing Charges
DebtExpenseIncludingDebtRefinancingCharges
275345000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
12583000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
132684000 USD
dva Equity In Earnings Loss Of Consolidated Affiliates
EquityInEarningsLossOfConsolidatedAffiliates
0 USD
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
406947000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
109697000 USD
us-gaap Profit Loss
ProfitLoss
516644000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
93804000 USD
us-gaap Net Income Loss
NetIncomeLoss
422840000 USD
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
5309477000 USD
us-gaap Health Care Organization Patient Service Revenue Provisionfor Bad Debts
HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts
23861000 USD
us-gaap Health Care Organization Patient Service Revenue Less Provision For Bad Debts
HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts
5285616000 USD
us-gaap Other Income
OtherIncome
450781000 USD
us-gaap Revenues
Revenues
5736397000 USD
us-gaap Costs And Expenses
CostsAndExpenses
4887519000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
848878000 USD
dva Debt Expense Including Debt Refinancing Charges
DebtExpenseIncludingDebtRefinancingCharges
233208000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6576000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
154605000 USD
dva Equity In Earnings Loss Of Consolidated Affiliates
EquityInEarningsLossOfConsolidatedAffiliates
0 USD
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
467641000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
63910000 USD
us-gaap Profit Loss
ProfitLoss
531551000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
85589000 USD
us-gaap Net Income Loss
NetIncomeLoss
445962000 USD
CY2019Q2 us-gaap Profit Loss
ProfitLoss
327157000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
13940000 USD
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
287491000 USD
CY2018Q2 us-gaap Profit Loss
ProfitLoss
306322000 USD
CY2018Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-49260000 USD
CY2018Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
257062000 USD
CY2018Q2 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
39046000 USD
CY2018Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
218016000 USD
us-gaap Profit Loss
ProfitLoss
516644000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1313000 USD
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
517957000 USD
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
93804000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
424153000 USD
us-gaap Profit Loss
ProfitLoss
531551000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-26792000 USD
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
504759000 USD
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
85589000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
419170000 USD
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3575638000 USD
CY2019Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
106772000 USD
CY2019Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2010801000 USD
CY2019Q2 dva Investments And Other Current Assets
InvestmentsAndOtherCurrentAssets
697418000 USD
CY2019Q2 us-gaap Assets Current
AssetsCurrent
6390629000 USD
CY2019Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3405315000 USD
CY2019Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2790885000 USD
CY2019Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
120574000 USD
CY2019Q2 us-gaap Equity Method Investments
EquityMethodInvestments
0 USD
CY2019Q2 us-gaap Due From Related Parties Noncurrent
DueFromRelatedPartiesNoncurrent
0 USD
CY2019Q2 us-gaap Investments And Other Noncurrent Assets
InvestmentsAndOtherNoncurrentAssets
358171000 USD
CY2019Q2 us-gaap Goodwill
Goodwill
6865386000 USD
CY2019Q2 us-gaap Assets
Assets
19930960000 USD
CY2019Q2 dva Current Liabilities
CurrentLiabilities
5706944000 USD
CY2019Q2 us-gaap Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
0 USD
CY2019Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2689249000 USD
CY2019Q2 dva Long Term Debt And Other Noncurrent
LongTermDebtAndOtherNoncurrent
6105965000 USD
CY2019Q2 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
1185733000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
4049298000 USD
CY2019Q2 us-gaap Minority Interest
MinorityInterest
193771000 USD
CY2019Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
4243069000 USD
CY2019Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19930960000 USD
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
323038000 USD
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
92382000 USD
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1858608000 USD
CY2018Q4 dva Investments And Other Current Assets
InvestmentsAndOtherCurrentAssets
760566000 USD
CY2018Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
5389565000 USD
CY2018Q4 us-gaap Assets Current
AssetsCurrent
8424159000 USD
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3393669000 USD
CY2018Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
118846000 USD
CY2018Q4 us-gaap Equity Method Investments
EquityMethodInvestments
0 USD
CY2018Q4 us-gaap Due From Related Parties Noncurrent
DueFromRelatedPartiesNoncurrent
0 USD
CY2018Q4 us-gaap Investments And Other Noncurrent Assets
InvestmentsAndOtherNoncurrentAssets
331618000 USD
CY2018Q4 us-gaap Goodwill
Goodwill
6841960000 USD
CY2018Q4 us-gaap Assets
Assets
19110252000 USD
CY2018Q4 dva Current Liabilities
CurrentLiabilities
3647402000 USD
CY2018Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
1243759000 USD
CY2018Q4 us-gaap Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
0 USD
CY2018Q4 dva Long Term Debt And Other Noncurrent
LongTermDebtAndOtherNoncurrent
9186052000 USD
CY2018Q4 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
1124641000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
3703442000 USD
CY2018Q4 us-gaap Minority Interest
MinorityInterest
204956000 USD
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3908398000 USD
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19110252000 USD
us-gaap Profit Loss
ProfitLoss
516644000 USD
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
234471000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
751115000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
373918000 USD
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
65970000 USD
us-gaap Proceeds From Sales Of Business Affiliate And Productive Assets
ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
3851381000 USD
dva Payments For Proceeds From Sale Of Investments In Securities And Other
PaymentsForProceedsFromSaleOfInvestmentsInSecuritiesAndOther
8801000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
3402692000 USD
dva Proceeds From Repayments Of Long Term Debt
ProceedsFromRepaymentsOfLongTermDebt
-1164109000 USD
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
0 USD
dva Payments For Other Financing Activities
PaymentsForOtherFinancingActivities
146444000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-1310553000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-77000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2843177000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
415420000 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3682410000 USD
us-gaap Profit Loss
ProfitLoss
531551000 USD
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
393024000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
924575000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
473977000 USD
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
89465000 USD
us-gaap Proceeds From Sales Of Business Affiliate And Productive Assets
ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
116241000 USD
dva Payments For Proceeds From Sale Of Investments In Securities And Other
PaymentsForProceedsFromSaleOfInvestmentsInSecuritiesAndOther
-23137000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-424064000 USD
dva Proceeds From Repayments Of Long Term Debt
ProceedsFromRepaymentsOfLongTermDebt
573981000 USD
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
0 USD
dva Payments For Other Financing Activities
PaymentsForOtherFinancingActivities
879890000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-305909000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-3473000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
191129000 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
518920000 USD
CY2019Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2010801000 USD
CY2019Q2 dva Investments And Other Current Assets
InvestmentsAndOtherCurrentAssets
697418000 USD
CY2019Q2 us-gaap Assets Current
AssetsCurrent
6390629000 USD
CY2019Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3405315000 USD
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
480148000 USD
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
5369217000 USD
us-gaap Health Care Organization Patient Service Revenue Provisionfor Bad Debts
HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts
15712000 USD
us-gaap Health Care Organization Patient Service Revenue Less Provision For Bad Debts
HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts
5353505000 USD
us-gaap Other Income
OtherIncome
232312000 USD
us-gaap Revenues
Revenues
5585817000 USD
us-gaap Costs And Expenses
CostsAndExpenses
4783424000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
802393000 USD
dva Debt Expense Including Debt Refinancing Charges
DebtExpenseIncludingDebtRefinancingCharges
275345000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
12583000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
132684000 USD
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
406947000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
109697000 USD
us-gaap Profit Loss
ProfitLoss
516644000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
93804000 USD
us-gaap Net Income Loss
NetIncomeLoss
422840000 USD
us-gaap Profit Loss
ProfitLoss
516644000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1313000 USD
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
517957000 USD
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
93804000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
424153000 USD
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3575638000 USD
CY2019Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
106772000 USD
CY2019Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2790885000 USD
CY2019Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
120574000 USD
CY2019Q2 us-gaap Investments And Other Noncurrent Assets
InvestmentsAndOtherNoncurrentAssets
358171000 USD
CY2019Q2 us-gaap Goodwill
Goodwill
6865386000 USD
CY2019Q2 us-gaap Assets
Assets
19930960000 USD
CY2019Q2 dva Current Liabilities
CurrentLiabilities
5706944000 USD
CY2019Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2689249000 USD
CY2019Q2 dva Long Term Debt And Other Noncurrent
LongTermDebtAndOtherNoncurrent
6105965000 USD
CY2019Q2 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
1185733000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
4049298000 USD
CY2019Q2 us-gaap Minority Interest
MinorityInterest
193771000 USD
CY2019Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
4243069000 USD
CY2019Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19930960000 USD
us-gaap Profit Loss
ProfitLoss
516644000 USD
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
234471000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
751115000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
373918000 USD
us-gaap Payments For Proceeds From Businesses And Interest In Affiliates
PaymentsForProceedsFromBusinessesAndInterestInAffiliates
65970000 USD
us-gaap Proceeds From Sales Of Business Affiliate And Productive Assets
ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
3851381000 USD
dva Payments For Proceeds From Sale Of Investments In Securities And Other
PaymentsForProceedsFromSaleOfInvestmentsInSecuritiesAndOther
8801000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
3402692000 USD
dva Proceeds From Repayments Of Long Term Debt
ProceedsFromRepaymentsOfLongTermDebt
-1164109000 USD
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
0 USD
dva Payments For Other Financing Activities
PaymentsForOtherFinancingActivities
146444000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-1310553000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-77000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2843177000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
415420000 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3682410000 USD

Files In Submission

Name View Source Status
0000927066-19-000133-index-headers.html Edgar Link pending
0000927066-19-000133-index.html Edgar Link pending
0000927066-19-000133.txt Edgar Link pending
0000927066-19-000133-xbrl.zip Edgar Link pending
dva-20190630.xsd Edgar Link pending
dva-20190630_cal.xml Edgar Link unprocessable
dva-20190630_def.xml Edgar Link unprocessable
dva-20190630_lab.xml Edgar Link unprocessable
dva-20190630_pre.xml Edgar Link unprocessable
dva-6301910q.htm Edgar Link pending
dva-6301910q_htm.xml Edgar Link completed
dva-63019ex311.htm Edgar Link pending
dva-63019ex312.htm Edgar Link pending
dva-63019ex321.htm Edgar Link pending
dva-63019ex322.htm Edgar Link pending
dva-63019xex101.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
logoa21.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R89.htm Edgar Link pending
R9.htm Edgar Link pending
R90.htm Edgar Link pending
R91.htm Edgar Link pending
R92.htm Edgar Link pending
R93.htm Edgar Link pending
R94.htm Edgar Link pending
R95.htm Edgar Link pending
R96.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending